News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Chinese Biotech Firm 3SBio Files For U.S. IPO
January 22, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Jan 19 (Reuters) - Chinese biotechnology firm 3SBio Inc. said on Friday it is seeking an initial public offering of 7.7 million American depositary shares (ADS) for between $12 and $14 per ADS.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Obesity
After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B
December 9, 2025
·
2 min read
·
Dan Samorodnitsky
China
With Chinese Assets in Hand, Pharma Is Wondering What Else Can Be Learned
December 9, 2025
·
3 min read
·
Annalee Armstrong
Venture capital
Lilly, Novo GLP-1 Pricing Plans Clear Runway For Future Competitors
December 3, 2025
·
2 min read
·
Annalee Armstrong
Gene editing
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD
December 1, 2025
·
1 min read
·
Tristan Manalac
